This afternoon we watched United Therapeutics drop -5.6% to a price of $229.72 per share. The Large-Cap Pharmaceutical company is now trading -21.4% below its average target price of $292.25. Analysts have set target prices ranging from $183.0 to $375.0 per share for United Therapeutics, and have given the stock an average rating of buy.
United Therapeutics's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.6%. The stock's short ratio is 3.81. The company's insiders own 1.72% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 97.0%. In conclusion, we believe there is positive market sentiment regarding United Therapeutics.
Institutions Invested in United Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-12-31 | Blackrock Inc. | 11% | 5,295,000 | $1,216,367,406 |
| 2023-12-31 | Vanguard Group Inc | 10% | 4,673,678 | $1,073,637,315 |
| 2023-12-31 | Wellington Management Group, LLP | 8% | 3,794,010 | $871,559,981 |
| 2023-12-31 | Avoro Capital Advisors LLC | 6% | 2,858,888 | $656,743,754 |
| 2023-12-31 | FMR, LLC | 5% | 2,321,040 | $533,189,311 |
| 2023-12-31 | Renaissance Technologies, LLC | 5% | 2,170,214 | $498,541,562 |
| 2023-12-31 | State Street Corporation | 4% | 1,947,177 | $447,305,502 |
| 2023-12-31 | Janus Henderson Group PLC | 2% | 870,119 | $199,883,737 |
| 2023-12-31 | Geode Capital Management, LLC | 2% | 779,762 | $179,126,927 |
| 2023-12-31 | Dimensional Fund Advisors LP | 1% | 561,950 | $129,091,154 |
